MaxCyte Minutes Newsletter

After interviewing Maher Masoud and Jim Brady, Kevin Davies, editor of GEN, presents in this article an exploration of MaxCyte’s history, its impact on the cell and gene therapy field—especially following the casgevy approval—and a glimpse into its future.

Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers

Today, MaxCyte has signed a new strategic platform license with Imugene Limited, a clinical-stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. This partnership will enable them to use our Flow Electroporation^® technology and ExPERT platform to advance novel cell therapies and potentially reach more patients. We are excited to support advancements of novel cell therapies to improve outcomes for cancer patients.